HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


At Supplement Regulation Table, Industry And FDA Target Dealing Out 'Quick Buck' Players

This article was originally published in The Rose Sheet

Executive Summary

FDA's ODSP, says Director Steven Tave, found "how much there is in common between what our goals are at FDA and what your goals are in the industry." Trade group executives suggest changes both for the industry and FDA, though none expect noncompliant firms to fall into line short of being forced off the market.

You may also be interested in...

Protein Powder Firm Faces Criminal Charges From Economic Adulteration

American Pure Whey says on its website, "we are temporarily discontinuing the sale of products. Please check back in 7 days and you will be able to order our products." But firm previously warned by FDA about GMP deficiencies might want to recalculate how long sales will be stopped due to 41-count indictment on criminal charges.

Supplement OWL Registry Counts On Peer Pressure To Spur Use

CRN-organized Supplement OWL launches with nearly 2,600 labels included and adds almost 500 more in its first week, though a much larger total is needed to offer drug store chains and other retailers access a broader perspective of products available in the US.

Consensus-Based Supplement GMP Standards In Fine-Tuning Phase

ANSI-approved, consensus-based standards for supplement GMPs set to debut in early 2017 should help reduce the overall number of audits required for the category, says the Global Retailer and Manufacturer Alliance, which has worked since 2014 to develop the standard.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts